Posted by Michael Wonder on 04 Apr 2017
Teva Announces FDA approval of Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease
3 April 2017 - Approval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a decade.
Teva Pharmaceutical Industries today announced that the U.S. FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease.
Previously referred to by the developmental name SD-809, Austedo is the first deuterated product approved by the FDA and only the second product approved in Huntington's disease. The product was previously granted orphan drug designation by the FDA.
